Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders

September 9, 2019

SAN DIEGO & WAYNE, Pa.--(BUSINESS WIRE)--Sep 9, 2019--

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a class action complaint against the company’s officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 8, 2018 and June 20, 2019. Aclaris, a pharmaceutical company, identifies, develops, and commercializes therapies for dermatological and immune-inflammatory diseases. Its lead product is ESKATA, a hydrogen peroxide topical solution that treats seborrheic keratosis.

If you suffered a loss as a result of Aclaris’ misconduct, click here.

Aclaris Therapeutics Accused of Making Misleading Claims in Video Advertisement

According to the complaint, in May 2018, Aclaris announced the launch of ESKATA, touting the product as the “first and only FDA-approved topical treatment for seborrheic keratosis.” Despite positive expectations, Aclaris acknowledged in its 2017 10-K that ESKATA was subject to post-marketing restrictions and that failure to comply with regulations could lead to penalties. In its subsequent filings with the SEC, Aclaris touted its revenue from its sale of ESKATA and consistently assured that there were no material changes in its risk factors. However, in reality, Aclaris’ advertising materials for ESKATA minimized its risks and overstated its efficacy, leaving the company vulnerable to regulatory scrutiny. This reality was realized on June 20, 2019, when the FDA issued a letter in response to a direct-to-consumer video interview with a paid Aclaris spokesperson, stating that Aclaris’ advertisement for ESKATA ”[made] false or misleading claims” about the product’s risks and efficacy by failing to mention risk of serious eye disorders or severe skin reactions. Since this news, Aclaris’ share price has fallen $3.99, almost 80%.

If you purchased Aclaris Therapeutics, Inc. (ACRS) securities between May 8, 2018 and June 20, 2019, you have until September 30, 2019, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
Shareholder Information Form

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190909005811/en/

CONTACT: Leo Kandinov

Robbins Arroyo LLP

5040 Shoreham Place

San Diego, CA 92122


(619) 525-3990 or Toll Free (800) 350-6003




SOURCE: Robbins Arroyo LLP

Copyright Business Wire 2019.

PUB: 09/09/2019 12:55 PM/DISC: 09/09/2019 12:55 PM


All contents © copyright 2019 The Associated Press. All rights reserved.